GSC 002219
Alternative Names: GSC-002219Latest Information Update: 03 Feb 2025
Price :
$50 *
At a glance
- Originator GeneScience Pharmaceuticals
- Class Antihypertensives
- Mechanism of Action Aldosterone synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Hypertension
Most Recent Events
- 05 Sep 2024 Preclinical trials in Hypertension in China (unspecified route)
- 05 Sep 2024 Adverse events, pharmacokinetics and pharmacodynamics data from preclinical trials in Hypertension presented at the Hypertension Scientific Session 2024 (HTN-2024)
- 05 Sep 2024 Genescience Pharmaceuticals plans a clinical trial for Hypertension in early 2025